Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline Share Value Plan (SVP).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on equity transactions.
- Share Sale Price: £16.73 per Ordinary Share (February 24, 2014).
- ADS Withholding Price: $55.69 per American Depositary Share (February 24, 2014).
Material Changes
The filing details specific sales and withholdings of shares to meet tax liabilities following the vesting of awards granted in 2011. There are no reported material changes to the company's financial position or operations in this document.
- Ordinary Shares Sold:
- Mr. R Connor: 3,869 shares
- Mr. P Thomson: 4,724 shares
- Mrs. V Whyte: 4,724 shares
- ADSs Withheld:
- Mr. J Ford: 2,276 ADSs
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification regarding Rule 12g3-2(b) and Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares sold or withheld by PDMRs to assess insider sentiment.
- Confirm the fair market value prices (£16.73 and $55.69) against market data for February 24, 2014.
- Note that these transactions were solely for tax liabilities related to 2011 awards, not discretionary sales.